BridgeMD
New treatment option for Colorectal Cancer (Diagnosis)
Official title Short-Term Nutritional Enhancement Combined With Health Education in Postoperative Colorectal Cancer Patients: A Randomized Controlled Trial
ClinicalTrials.gov ID: NCT07087561
What this study is testing
What is Personalized Parenteral Nutritional Supplementation?
Personalized Parenteral Nutritional Supplementation is an investigational medicine, given as an once-weekly infusion into a vein, being studied as a potential treatment for colorectal cancer (diagnosis).
Also referred to as PN.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This clinical study aims to evaluate whether short-term personalized nutritional support, when combined with structured health education, can improve nutritional status, quality of life, and clinical outcomes in patients who have undergone surgery for colorectal cancer (CRC). Colorectal cancer is one of the most common cancers worldwide, and many patients experience malnutrition and poor physical condition during treatment, which can negatively affect recovery and long-term survival.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Signed informed consent
- Age ≥ 18 years
- Pathologically confirmed diagnosis of colon or rectal cancer
- Mentally alert and capable of communication
- Willing to participate in follow-up, with an estimated life expectancy of more than 6 months
You likely can't join if
- Nutritional risk screening score of mPG-SGA \< 2 or NRS-2002 \< 3
- Diagnosed with AIDS
- History of organ transplantation
- Pregnant or breastfeeding women
- Concurrent participation in another treatment clinical trial
- Inability to care for oneself independently
See the full eligibility criteria
- Signed informed consent
- Age ≥ 18 years
- Pathologically confirmed diagnosis of colon or rectal cancer
- Mentally alert and capable of communication
- Willing to participate in follow-up, with an estimated life expectancy of more than 6 months
- Cancer stage IIa, IIb, or IIIa
- Nutritional risk screening score of mPG-SGA \< 2 or NRS-2002 \< 3
- Diagnosed with AIDS
- History of organ transplantation
- Pregnant or breastfeeding women
- Concurrent participation in another treatment clinical trial
- Inability to care for oneself independently
- Inability to engage in physical activity during the perioperative period
- Severe comorbid conditions (e.g., uncontrolled cardiovascular disease, severe hepatic or renal dysfunction)
- Known allergy or intolerance to components of the nutritional supplements used in the study
The study team makes the final eligibility decision.
Where it's taking place
- Xi'an, Shaanxi, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Xi'an, Shaanxi, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.